# 2026-04252: Updated ICH Guidance for Postapproval Drug Safety Reporting

2026-04252, E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-04, effective 2026-03-04; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04252
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04252
- Title: E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 10619
- Published: 2026-03-04
- Effective: 2026-03-04
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Updated ICH Guidance for Postapproval Drug Safety Reporting

## Summary

The FDA just released new rules for drug companies on how to track and report safety info after a drug is approved. This update includes fresh ways to use data from places like social media and patient programs to keep medicines safe. Drug makers should get ready to follow these clearer, modern rules starting now, helping protect patients without extra costs.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance updates the 2003 guidance titled "E2D Post- Approval Safety Data Management: Definitions and Standards for Expedited Reporting," by clarifying the use of new or increasingly used data sources (e.g., social media, market research programs, patient support programs). This final guidance clarifies the use of new postapproval safety sources and update terminology and standards for postapproval adverse event reporting. The guidance replaces the draft guidance "E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports" issued on March 14, 2024, and the final guidance issued September 15, 2003.

## Effects PRIA read

- New Safety Data Sources Allowed: benefit, medium. The FDA released final guidance on March 4, 2026, that clarifies how companies and regulators may use new postapproval safety data sources — for example, social media, market research programs, and patient support programs — when managing and reporting individual case safety reports. The guidance u…
- Global Harmonization May Increase Access: benefit, medium. The guidance, prepared under the International Council for Harmonisation (ICH) and announced March 4, 2026, states that harmonized guidelines help ensure safe, effective, high-quality medicines, reduce duplicative clinical studies, and increase the availability of medications. FDA notes the guidanc…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04252 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/04/2026-04252/e2dr1-postapproval-safety-data-definitions-and-standards-for-management-and-reporting-of-individual)
- [2026-04252 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-04/pdf/2026-04252.pdf)

## Related
- [Previous: 2026-04251, Petition for Exemption; Summary of Petition Received; The Boeing Company](https://policyrisk.com/federal-register/2026-04251)
- [Next: 2026-04253, M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-…](https://policyrisk.com/federal-register/2026-04253)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04252 (as of 2026-06-08).
